Zhu, Y.-C., Xu, C.-W., Ye, X.-Q., et al. (2016) Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: A Case Report and Review of the Literature. OncoTargets and Therapy, 9, 4301-4305.
https://doi.org/10.2147/OTT.S109415

has been cited by the following article:

• TITLE: A Case Report of a Rare Sarcomatoid Poorly Differentiated Adenocarcinoma Harboring Concurrent Mutations in the ROS1, EGFR, ARID1A, and NFKBIA Genes in the Lung

  AUTHORS: Jinlin Du, Lanlan Li, Shiqi Song, Siqin Chen, Yaxian Yang, Jian Huang

  KEYWORDS: Non-Small Cell Lung Cancer, ROS1, EGFR, Sarcomatoid

  JOURNAL NAME: Journal of Cancer Therapy, Vol.15 No.5, May 23, 2024

  ABSTRACT: ROS1 and EGFR are primary oncogenic drivers in non-small cell lung cancer (NSCLC) pathogenesis. However, EGFR mutations and ROS1 fusions are generally mutually exclusive in NSCLC, leading to a negligible probability of their co-occurrence. Consequently, clinical data and treatment strategies for their simultaneous presence are remarkably scarce. This report details the first recorded case of a sarcomatoid, poorly differentiated lung adenocarcinoma harboring both a ROS1 fusion and an EGFR mutation, alongside ARID1A and NFKBIA gene mutations. Moreover, this case study encompasses a review of instances featuring concurrent ROS1 and EGFR mutations. The identified genetic alterations in ROS1, EGFR, ARID1A, and NFKBIA are pivotal in the etiology of NSCLC. These mutations significantly influence disease progression and are essential for the development of personalized therapeutic approaches. Recognizing the unique genetic profiles in patients permits healthcare providers to devise customized treatment regimens that target these specific mutations, thereby enhancing patient outcomes in NSCLC.